{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:03:55Z","timestamp":1781103835318,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medicine and health discipline platform project of zhejiang province","award":["2018RC019"],"award-info":[{"award-number":["2018RC019"]}]},{"name":"Medicine and health science project of zhejiang province","award":["2020KY483"],"award-info":[{"award-number":["2020KY483"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to evaluate the efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization (DEB-TACE) versus regorafenib monotherapy in colorectal cancer liver metastases (CRLM) patients who failed standard treatment regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Totally, 76 eligible CRLM patients were analyzed, among which 42 patients received regorafenib monotherapy (as regorafenib group) and 34 patients received regorafenib plus DEB-TACE (as regorafenib plus DEB-TACE group).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Objective response rate (35.3% versus 7.1%, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and disease control rate (76.5% versus 47.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.011) were both increased in regorafenib plus DEB-TACE group compared with regorafenib group; meanwhile, negative conversion rate of carcinoembryonic antigen (66.7% versus 28.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.008) after treatment was elevated in regorafenib plus DEB-TACE group compared with regorafenib group. Notably, progression-free survival (PFS) (median value: 7.6 versus 4.1\u00a0months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and overall survival (OS) (median value: 15.7 versus 9.2\u00a0months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were both higher in regorafenib plus DEB-TACE group compared with regorafenib group. Furthermore, liver function indexes (alanine transaminase, aspartate aminotransferase, and cholinesterase levels) after treatment were all similar between the two groups (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). In addition, the occurrences of upper abdominal distending pain (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), nausea and vomiting (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) and fever (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) were higher in regorafenib plus DEB-TACE group compared with regorafenib group, while the majority of these adverse events were mild and tolerable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Regorafenib plus DEB-TACE is superior to regorafenib monotherapy regarding treatment response, PFS and OS, while induces tolerable post-embolization syndrome in CRLM patients who fail standard treatment regimens.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03708-1","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T04:15:31Z","timestamp":1627100131000},"page":"2993-3002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens"],"prefix":"10.1007","volume":"147","author":[{"given":"Fei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-8854","authenticated-orcid":false,"given":"Guoliang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"key":"3708_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/TCRM.S122480","volume":"13","author":"ML Affronti","year":"2017","unstructured":"Affronti ML et al (2017) A phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. Ther Clin Risk Manag 13:33\u201340. https:\/\/doi.org\/10.2147\/TCRM.S122480","journal-title":"Ther Clin Risk Manag"},{"key":"3708_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000503095","volume":"12","author":"F Azam","year":"2019","unstructured":"Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, Bukhari N (2019) Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol 12:728\u2013736. https:\/\/doi.org\/10.1159\/000503095","journal-title":"Case Rep Oncol"},{"key":"3708_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s00270-015-1093-4","volume":"38","author":"U Carling","year":"2015","unstructured":"Carling U et al (2015) Transarterial chemoembolization of liver metastases from uveal melanoma using irinotecan-loaded beads: treatment response and complications. Cardiovasc Intervent Radiol 38:1532\u20131541. https:\/\/doi.org\/10.1007\/s00270-015-1093-4","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3708_CR5","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","volume":"27","author":"D Do Minh","year":"2017","unstructured":"Do Minh D et al (2017) Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol 27:4995\u20135005. https:\/\/doi.org\/10.1007\/s00330-017-4856-2","journal-title":"Eur Radiol"},{"key":"3708_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","volume":"211","author":"TJ Ettrich","year":"2018","unstructured":"Ettrich TJ, Seufferlein T (2018) Regorafenib. Recent Results Cancer Res 211:45\u201356. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_3","journal-title":"Recent Results Cancer Res"},{"key":"3708_CR7","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"3708_CR8","first-page":"2077","volume":"55","author":"G Fiorentini","year":"2008","unstructured":"Fiorentini G, Aliberti C, Benea G, Montagnani F, Mambrini A, Ballardini PL, Cantore M (2008) TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 55:2077\u20132082","journal-title":"Hepatogastroenterology"},{"key":"3708_CR9","first-page":"131","volume":"23","author":"G Fiorentini","year":"2009","unstructured":"Fiorentini G et al (2009) Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 23:131\u2013137","journal-title":"In Vivo"},{"key":"3708_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/526178","volume":"2014","author":"G Giordano","year":"2014","unstructured":"Giordano G et al (2014) Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract 2014:526178. https:\/\/doi.org\/10.1155\/2014\/526178","journal-title":"Gastroenterol Res Pract"},{"key":"3708_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"key":"3708_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00270-013-0632-0","volume":"37","author":"P Huppert","year":"2014","unstructured":"Huppert P, Wenzel T, Wietholtz H (2014) Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol 37:154\u2013164. https:\/\/doi.org\/10.1007\/s00270-013-0632-0","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3708_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx263.024","author":"MOC Juan","year":"2017","unstructured":"Juan MOC, Hler L, Scheithauer W, Metges JP, Ducreux M (2017) PD-025Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): interim analysis from the prospective, observational CORRELATE study. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx263.024","journal-title":"Ann Oncol"},{"key":"3708_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.21037\/jgo.2019.08.06","volume":"10","author":"AWC Kow","year":"2019","unstructured":"Kow AWC (2019) Hepatic metastasis from colorectal cancer. J Gastrointest Oncol 10:1274\u20131298. https:\/\/doi.org\/10.21037\/jgo.2019.08.06","journal-title":"J Gastrointest Oncol"},{"key":"3708_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"3708_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16:619\u2013629. https:\/\/doi.org\/10.1016\/S1470-2045(15)70156-7","journal-title":"Lancet Oncol"},{"key":"3708_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1477-7819-7-80","volume":"7","author":"RC Martin","year":"2009","unstructured":"Martin RC et al (2009) Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7:80. https:\/\/doi.org\/10.1186\/1477-7819-7-80","journal-title":"World J Surg Oncol"},{"key":"3708_CR18","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2217\/fon-2018-0136","volume":"14","author":"F Melchiorre","year":"2018","unstructured":"Melchiorre F et al (2018) DEB-TACE: a standard review. Future Oncol 14:2969\u20132984. https:\/\/doi.org\/10.2217\/fon-2018-0136","journal-title":"Future Oncol"},{"key":"3708_CR4","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 (2010). http:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 22 Jul 2021"},{"key":"3708_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00270-019-02219-4","volume":"42","author":"A Ngo","year":"2019","unstructured":"Ngo A et al (2019) Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: a bi-institutional analysis of 125 treatments in 53 patients. Cardiovasc Intervent Radiol 42:979\u2013990. https:\/\/doi.org\/10.1007\/s00270-019-02219-4","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3708_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"JL Raoul","year":"2019","unstructured":"Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T (2019) Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 72:28\u201336. https:\/\/doi.org\/10.1016\/j.ctrv.2018.11.002","journal-title":"Cancer Treat Rev"},{"key":"3708_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103:914\u2013921. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01712.x","journal-title":"Am J Gastroenterol"},{"key":"3708_CR22","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.21873\/anticanres.11254","volume":"36","author":"A Suzuki","year":"2016","unstructured":"Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K, Itoh Y (2016) Control of nausea and vomiting in patients with colorectal cancer receiving chemotherapy with moderate emetic risk. Anticancer Res 36:6527\u20136533. https:\/\/doi.org\/10.21873\/anticanres.11254","journal-title":"Anticancer Res"},{"issue":"Suppl 5","key":"3708_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/annonc\/mdq222","volume":"21","author":"E Van Cutsem","year":"2010","unstructured":"Van Cutsem E, Nordlinger B, Cervantes A, EGW Group (2010) Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 21(Suppl 5):93\u201397. https:\/\/doi.org\/10.1093\/annonc\/mdq222","journal-title":"Ann Oncol"},{"key":"3708_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LG van der Geest","year":"2015","unstructured":"van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH (2015) Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 32:457\u2013465. https:\/\/doi.org\/10.1007\/s10585-015-9719-0","journal-title":"Clin Exp Metastasis"},{"key":"3708_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07253-2","author":"TJ Vogl","year":"2020","unstructured":"Vogl TJ, Marko C, Langenbach MC, Naguib NNN, Filmann N, Hammerstingl R, Gruber-Rouh T (2020) Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-020-07253-2","journal-title":"Eur Radiol"},{"key":"3708_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jcmgh.2017.01.006","volume":"3","author":"LR Zarour","year":"2017","unstructured":"Zarour LR et al (2017) Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol 3:163\u2013173. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.01.006","journal-title":"Cell Mol Gastroenterol Hepatol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03708-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03708-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03708-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T15:17:09Z","timestamp":1630077429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03708-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3708"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03708-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflict of interest was reported by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Medical Ethics Committee of the Zhejiang cancer hospital, China. All included patients provided signed informed consents prior to participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}